Glucose-Linked Chlorin E6-Conjugated Trastuzumab for Targeted Photodynamic Therapy in HER2-Posit

03 Apr 20264 min read1 viewsJournal Feed

GIST (Key Takeaways)

by Makiko Sasaki, Mamoru Tanaka, Akihiro Nomoto, Ryusei Yamasaki, Tomokazu Yoshimura, Shigenobu Yano, Yasunari Sasaki, Yuki Kojima, Taketo Suzuki, Hirotada Nishie, Keiji Ozeki, Takaya Shimura, Eiji Kubota, Hiromi Kataoka Photodynamic therapy (PDT) is an anti-cancer therapy that employs a photosensitizer (PS) and an optimal wavelength of light, causing a photochemical reaction that releases reactive oxygen species, thereby inducing cancer cell death via oxidative stress. Because light irradiation is limited to the tumor site, PDT has minimal adverse effects.
The cancer cell selectivity of the PS is important for reducing damage to the normal mucosa caused by scattered light. Antibody-drug conjugates (ADC) are novel anti-cancer therapies that combine a monoclonal tumor-surface-receptor-targeting antibody with a drug bonded through chemical linkers.
ADCs enable the targeted delivery of a variety of drugs to cancer cells while minimizing their delivery to healthy tissues. One such tumor surface receptor is the human epidermal growth factor receptor 2 (HER2), which is of interest in the treatment of many cancers, including gastrointestinal cancer.

The work reports development and evaluation of a novel photosensitizer conjugate for photodynamic therapy (PDT) aimed at improving tumor selectivity and minimizing surrounding mucosal damage.
Researchers engineered a glucose-linked chlorin e6 conjugated to trastuzumab (G-Ce6-trastuzumab), pairing a tumor-targeting antibody with a photosensitizer linked via a glucose moiety.

G-Ce6-trastuzumab combines an established photosensitizer, chlorin e6 (Ce6), with a glucose linker and the anti-HER2 antibody trastuzumab.
The design intends to direct PDT activity more specifically to HER2-expressing cancer cells, leveraging both antibody-targeting and the intracellular routing of the photosensitizer.

The anti-cancer effects were assessed in vitro using two cell lines that differ in HER2 expression: NCI-N87 (high HER2) and MKN-45 (low HER2).
The internalization of G-Ce6-trastuzumab occurred at intracellular organelles within cancer cells.

Cell viability was measured with the WST-8 assay following PDT.
Results indicated a significantly greater cytotoxic effect of G-Ce6-trastuzumab compared with the conventional photosensitizer G-Ce6 in HER2-high-expression cells.
The implication is enhanced selectivity for HER2-high-expressing cells, potentially reducing damage to adjacent normal mucosa.

The study positions G-Ce6-trastuzumab as a promising photosensitizer for PDT, aiming to combine targeted antibody delivery with light-activated cytotoxicity.
The authors suggest that strong selectivity for HER2-high-expression cells could translate into improved therapeutic precision for gastrointestinal cancers expressing HER2.

The provided content focuses on in vitro findings in two cell lines and does not report in vivo outcomes, comprehensive safety data, or clinical performance.
The source does not include explicit clinical endpoints, dosing parameters, or translational feasibility assessments beyond the cellular model.